aminocaproic acid has been researched along with Blood Loss, Postoperative in 72 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to compare 2 different doses of ε-aminocaproic acid (EACA) and assess their relative efficacy and safety in children undergoing corrective surgery for tetralogy of Fallot (TOF)." | 9.17 | Comparison of different doses of ε-aminocaproic acid in children for tetralogy of Fallot surgery: clinical efficacy and safety. ( Kiran, U; Lakshmy, R; Makhija, N; Sarupria, A, 2013) |
| "To investigate the incidence of postoperative generalized seizures in patients undergoing aortic valve replacement (AVR) under extracorporeal circulation, who received either high-dose tranexamic acid (TXA) or epsilon aminocaproic acid (EACA) as an antifibrinolytic agent." | 7.77 | High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. ( Beyersdorf, F; Keyl, C; Lehane, C; Stampf, S; Trenk, D; Uhl, R; Wiesenack, C, 2011) |
| "Prospective evaluation of fibrinogen levels before surgery and after surgery in patients with idiopathic scoliosis undergoing posterior spinal fusion (PSF) and segmental spinal instrumentation (SSI) who received Amicar to decrease perioperative blood loss." | 7.74 | Fibrinogen levels following Amicar in surgery for idiopathic scoliosis. ( Armstrong, DG; Florentino-Pineda, I; Poe-Kochert, C; Thompson, GH, 2007) |
| " We report four neonates (one with massive postsurgical hemorrhage after ileostomy and three with severe pulmonary hemorrhage in the course of mechanical ventilation for meconium aspiration syndrome, congenital heart disease and during postoperative resuscitation after cardiac surgery for congenital heart disease) who were successfully treated with multiple administration of rFVIIa (120 microg/kg per dose) and antifibrinolytic therapy - aminocaproic acid (100 mg/kg per dose)." | 7.73 | Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage. ( Filipović-Grcić, B; Grizelj, R; Luetić, T; Sarić, D; Vuković, J, 2006) |
| "In patients with confirmed or suspected type 1 von Willebrand disease (VWD), adenotonsillectomy has been reported to be associated with a rate of peri-operative hemorrhage between 8 and 23%." | 5.38 | Haemostasis prophylaxis using single dose desmopressin acetate and extended use epsilon aminocaproic acid for adenotonsillectomy in patients with type 1 von Willebrand disease. ( Dimichele, DM; Hsu, F; Santoro, C, 2012) |
| "The purpose of this study was to compare 2 different doses of ε-aminocaproic acid (EACA) and assess their relative efficacy and safety in children undergoing corrective surgery for tetralogy of Fallot (TOF)." | 5.17 | Comparison of different doses of ε-aminocaproic acid in children for tetralogy of Fallot surgery: clinical efficacy and safety. ( Kiran, U; Lakshmy, R; Makhija, N; Sarupria, A, 2013) |
| "To investigate the incidence of postoperative generalized seizures in patients undergoing aortic valve replacement (AVR) under extracorporeal circulation, who received either high-dose tranexamic acid (TXA) or epsilon aminocaproic acid (EACA) as an antifibrinolytic agent." | 3.77 | High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. ( Beyersdorf, F; Keyl, C; Lehane, C; Stampf, S; Trenk, D; Uhl, R; Wiesenack, C, 2011) |
| "Prospective evaluation of fibrinogen levels before surgery and after surgery in patients with idiopathic scoliosis undergoing posterior spinal fusion (PSF) and segmental spinal instrumentation (SSI) who received Amicar to decrease perioperative blood loss." | 3.74 | Fibrinogen levels following Amicar in surgery for idiopathic scoliosis. ( Armstrong, DG; Florentino-Pineda, I; Poe-Kochert, C; Thompson, GH, 2007) |
| " We report four neonates (one with massive postsurgical hemorrhage after ileostomy and three with severe pulmonary hemorrhage in the course of mechanical ventilation for meconium aspiration syndrome, congenital heart disease and during postoperative resuscitation after cardiac surgery for congenital heart disease) who were successfully treated with multiple administration of rFVIIa (120 microg/kg per dose) and antifibrinolytic therapy - aminocaproic acid (100 mg/kg per dose)." | 3.73 | Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage. ( Filipović-Grcić, B; Grizelj, R; Luetić, T; Sarić, D; Vuković, J, 2006) |
| " Antifibrinolytic drugs are part of a multifaceted approach aimed at reducing bleeding, though sufficiently sized pediatric studies are sparse, and dosing algorithms are heterogeneous." | 2.82 | Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis. ( Hunt, BJ; Murdoch, IA; Sangaran, DP; Siemens, K; Tibby, SM, 2022) |
| " Few studies found adverse events, and no difference in incidence or type of adverse events was seen between the antifibrinolytic and the placebo group." | 2.72 | Efficacy and Safety of Antifibrinolytic Drugs in Pediatric Surgery: A Systematic Review. ( Fenger-Eriksen, C; Hansen, AK; Hovgesen, NT; Hvas, AM; Larsen, JB, 2021) |
| "The median postoperative blood loss 24 h postoperatively was reduced from 450 mL in the placebo group to 180 mL for aprotinin (60% reduction, P < 0." | 2.71 | Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty--a prospective randomized double-blind placebo-controlled study. ( Crawford, R; Crawford, S; Hatcher, S; Ray, M; Whitehouse, SL, 2005) |
| "This meta-analysis demonstrated that EACA could be safe and potentially efficacious for reducing blood loss and transfusions volume in patients with spinal deformity surgeries when compared with placebo." | 2.61 | The Efficacy and Safety of Epsilon-Aminocaproic Acid for Blood Loss and Transfusions in Spinal Deformity Surgery: A Meta-Analysis. ( Chen, R; Gong, M; Xiang, Z, 2019) |
| "A total of 59 participants with haemophilia undergoing dental extraction were involved." | 2.55 | Preventing perioperative bleeding in patients with inherited bleeding disorders. ( Beacher, N; Watterson, C, 2017) |
| "Excessive postoperative blood loss after cardiopulmonary bypass is a common problem, especially in patients suffering from congenital heart diseases." | 2.52 | Epsilon aminocaproic acid reduces blood transfusion and improves the coagulation test after pediatric open-heart surgery: a meta-analysis of 5 clinical trials. ( Li, Q; Lu, J; Meng, H; Meng, Z; Pribis, JP; Sun, Y; Zhu, C, 2015) |
| " Analysis of data is complicated as the dosing scheme, especially for tranexamic acid, varies extremely and the agents are highly overdosed in most relevant trials." | 2.47 | Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era. ( Koster, A; Schirmer, U, 2011) |
| "Tranexamic acid (TXA) has long been the antifibrinolytic hemostatic drug of choice for orthopedic surgery." | 1.91 | Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs. ( Haibier, A; Qin, Q; Ran, J; Ren, Z; Yusufu, A; Zhang, Z; Zhou, Y, 2023) |
| "In patients with confirmed or suspected type 1 von Willebrand disease (VWD), adenotonsillectomy has been reported to be associated with a rate of peri-operative hemorrhage between 8 and 23%." | 1.38 | Haemostasis prophylaxis using single dose desmopressin acetate and extended use epsilon aminocaproic acid for adenotonsillectomy in patients with type 1 von Willebrand disease. ( Dimichele, DM; Hsu, F; Santoro, C, 2012) |
| "Although the fourfold risk for seizures using TXA was not significant, we currently use EACA in paediatric cardiac surgery." | 1.37 | Tranexamic acid versus ɛ-aminocaproic acid: efficacy and safety in paediatric cardiac surgery. ( Breuer, T; Gertler, R; Hapfelmeier, A; Hess, J; Lange, R; Martin, K; Schreiber, C; Wiesner, G, 2011) |
| " Although plasma EACA concentrations greater than 130 microg/mL were consistently achieved, we observed a marked variability (more than sixfold) in plasma concentrations and bleeding outcomes despite the use of a weight-based dosing regimen." | 1.30 | epsilon-Aminocaproic acid plasma levels during cardiopulmonary bypass. ( Ayuso, L; Bennett-Guerrero, E; Canada, AT; Mythen, MG; Newman, MF; Reves, JG; Sorohan, JG, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.78) | 18.7374 |
| 1990's | 12 (16.67) | 18.2507 |
| 2000's | 21 (29.17) | 29.6817 |
| 2010's | 30 (41.67) | 24.3611 |
| 2020's | 7 (9.72) | 2.80 |
| Authors | Studies |
|---|---|
| Siemens, K | 1 |
| Sangaran, DP | 1 |
| Hunt, BJ | 1 |
| Murdoch, IA | 1 |
| Tibby, SM | 1 |
| Schertz, K | 1 |
| Karam, O | 1 |
| Demetres, M | 1 |
| Mayadunna, S | 1 |
| Faraoni, D | 2 |
| Nellis, ME | 1 |
| Yusufu, A | 1 |
| Haibier, A | 1 |
| Ren, Z | 1 |
| Qin, Q | 1 |
| Zhang, Z | 1 |
| Zhou, Y | 1 |
| Ran, J | 1 |
| Bradley, KE | 1 |
| Ryan, SP | 1 |
| Penrose, CT | 1 |
| Grant, SA | 1 |
| Wellman, SS | 2 |
| Attarian, DE | 1 |
| Green, CL | 2 |
| Risoli, T | 1 |
| Bolognesi, MP | 1 |
| Morales-Avalos, R | 2 |
| Ramos-Morales, T | 2 |
| Espinoza-Galindo, AM | 2 |
| Garay-Mendoza, D | 1 |
| Peña-Martínez, VM | 2 |
| Marfil-Rivera, LJ | 1 |
| Garza-Ocañas, L | 1 |
| Acosta-Olivo, C | 2 |
| Cerda-Barbosa, JK | 1 |
| Valdés-González, NL | 1 |
| Vílchez-Cavazos, F | 2 |
| Tripathy, SK | 1 |
| Rao, PB | 1 |
| Nanda, SN | 1 |
| Nayak, C | 1 |
| Samal, BP | 1 |
| Jain, M | 1 |
| Srinivasan, A | 1 |
| Hota, D | 1 |
| García-Pedro, JA | 1 |
| Morcos-Sandino, M | 1 |
| Silva-Ramos, HNG | 1 |
| Rodríguez-Torres, RA | 1 |
| Hovgesen, NT | 1 |
| Larsen, JB | 1 |
| Fenger-Eriksen, C | 1 |
| Hansen, AK | 1 |
| Hvas, AM | 1 |
| Watterson, C | 1 |
| Beacher, N | 1 |
| Hobbs, JC | 1 |
| Welsby, IJ | 1 |
| Dhakal, IB | 1 |
| Harper, RA | 1 |
| Sucher, MG | 1 |
| Giordani, M | 1 |
| Nedopil, AJ | 1 |
| Boese, CK | 1 |
| Centeno, L | 1 |
| Walters, RW | 1 |
| da Silva, RV | 1 |
| Gadelha, TB | 1 |
| Luiz, RR | 1 |
| Torres, SR | 1 |
| Chen, R | 1 |
| Xiang, Z | 1 |
| Gong, M | 1 |
| Riaz, O | 1 |
| Aqil, A | 1 |
| Asmar, S | 1 |
| Vanker, R | 1 |
| Hahnel, J | 1 |
| Brew, C | 1 |
| Grogan, R | 1 |
| Radcliffe, G | 1 |
| Ortmann, E | 1 |
| Besser, MW | 1 |
| Klein, AA | 1 |
| Cohen, HV | 2 |
| Figueroa, R | 1 |
| Quek, SY | 1 |
| Abbas, AM | 1 |
| Scepansky, E | 1 |
| Othman, M | 1 |
| Smith, H | 1 |
| Lu, J | 1 |
| Meng, H | 1 |
| Meng, Z | 1 |
| Sun, Y | 1 |
| Pribis, JP | 1 |
| Zhu, C | 1 |
| Li, Q | 1 |
| McLawhorn, AS | 1 |
| Levack, AE | 1 |
| Fields, KG | 1 |
| Sheha, ED | 1 |
| DelPizzo, KR | 1 |
| Sink, EL | 1 |
| Choudhuri, P | 1 |
| Biswas, BK | 1 |
| van Galen, KP | 1 |
| Engelen, ET | 1 |
| Mauser-Bunschoten, EP | 1 |
| van Es, RJ | 1 |
| Schutgens, RE | 1 |
| Blaine, KP | 1 |
| Press, C | 1 |
| Lau, K | 1 |
| Sliwa, J | 1 |
| Rao, VK | 1 |
| Hill, C | 1 |
| Thompson, GH | 2 |
| Florentino-Pineda, I | 2 |
| Poe-Kochert, C | 2 |
| Armstrong, DG | 2 |
| Son-Hing, J | 1 |
| Henry, D | 1 |
| Carless, P | 1 |
| Fergusson, D | 1 |
| Laupacis, A | 1 |
| Berenholtz, SM | 1 |
| Pham, JC | 1 |
| Garrett-Mayer, E | 1 |
| Atchison, CW | 1 |
| Kostuik, JP | 1 |
| Cohen, DB | 1 |
| Nundy, S | 1 |
| Dorman, T | 1 |
| Ness, PM | 1 |
| Klag, MJ | 1 |
| Pronovost, PJ | 1 |
| Kebaish, KM | 1 |
| Fogarty, PF | 1 |
| Kouides, P | 1 |
| Eubanks, JD | 1 |
| Lieberman, BL | 1 |
| Kennedy, MK | 1 |
| Lorenzo, DR | 1 |
| Reed, LJ | 1 |
| Adamo, AK | 1 |
| Cardo, VA | 1 |
| Badner, VM | 1 |
| Raghunathan, K | 1 |
| Connelly, NR | 1 |
| Kanter, GJ | 1 |
| Koster, A | 1 |
| Schirmer, U | 1 |
| Martin, K | 3 |
| Breuer, T | 1 |
| Gertler, R | 3 |
| Hapfelmeier, A | 1 |
| Schreiber, C | 3 |
| Lange, R | 1 |
| Hess, J | 1 |
| Wiesner, G | 3 |
| Keyl, C | 1 |
| Uhl, R | 1 |
| Beyersdorf, F | 1 |
| Stampf, S | 1 |
| Lehane, C | 1 |
| Wiesenack, C | 1 |
| Trenk, D | 1 |
| Sterner, A | 1 |
| MacGuill, M | 2 |
| Hörer, J | 1 |
| Vogt, M | 2 |
| Tassani, P | 2 |
| Santoro, C | 1 |
| Hsu, F | 1 |
| Dimichele, DM | 1 |
| Liermann, H | 1 |
| Mayr, NP | 1 |
| Marín, LM | 1 |
| Iazbik, MC | 1 |
| Zaldivar-Lopez, S | 1 |
| Guillaumin, J | 1 |
| McLoughlin, MA | 1 |
| Couto, CG | 1 |
| Sarupria, A | 1 |
| Makhija, N | 1 |
| Lakshmy, R | 2 |
| Kiran, U | 2 |
| Balaguer, JM | 1 |
| Yu, C | 1 |
| Byrne, JG | 1 |
| Ball, SK | 1 |
| Petracek, MR | 1 |
| Brown, NJ | 1 |
| Pretorius, M | 1 |
| Stassano, P | 1 |
| Musumeci, A | 1 |
| Santise, G | 1 |
| Gagliardi, C | 1 |
| Montalto, A | 1 |
| Spampinato, N | 1 |
| Jy, W | 1 |
| Gagliano-DeCesare, T | 1 |
| Kett, DH | 1 |
| Horstman, LL | 1 |
| Jimenez, JJ | 1 |
| Ruiz-Dayao, Z | 1 |
| Santos, ES | 1 |
| Ahn, YS | 1 |
| KOLLER, F | 1 |
| SCHMUTZLER, R | 1 |
| Chauhan, S | 1 |
| Das, SN | 1 |
| Bisoi, A | 1 |
| Kale, S | 2 |
| Arora, RC | 1 |
| Légaré, JF | 1 |
| Buth, KJ | 1 |
| Sullivan, JA | 1 |
| Hirsch, GM | 1 |
| Blanco-Carrion, J | 1 |
| Liñares-Gonzalez, A | 1 |
| Batalla-Vazquez, P | 1 |
| Diz-Dios, P | 1 |
| Ray, M | 1 |
| Hatcher, S | 1 |
| Whitehouse, SL | 1 |
| Crawford, S | 1 |
| Crawford, R | 1 |
| Wu, P | 1 |
| Sharma, V | 1 |
| Talwar, S | 1 |
| Choudhary, SK | 1 |
| Kumar, AS | 1 |
| Guldbakke, KK | 1 |
| Schanbacher, CF | 1 |
| Grizelj, R | 1 |
| Vuković, J | 1 |
| Filipović-Grcić, B | 1 |
| Sarić, D | 1 |
| Luetić, T | 1 |
| Alberca, I | 1 |
| Asuero, MS | 1 |
| Bóveda, JL | 1 |
| Carpio, N | 1 |
| Contreras, E | 1 |
| Fernández-Mondéjar, E | 1 |
| Forteza, A | 1 |
| García-Erce, JA | 1 |
| García de Lorenzo, A | 1 |
| Gomar, C | 1 |
| Gómez, A | 1 |
| Llau, JV | 1 |
| López-Fernández, MF | 1 |
| Moral, V | 1 |
| Muñoz, M | 1 |
| Páramo, JA | 1 |
| Torrabadella, P | 1 |
| Quintana, M | 1 |
| Sánchez, C | 1 |
| Zufferey, P | 1 |
| Merquiol, F | 1 |
| Laporte, S | 1 |
| Decousus, H | 1 |
| Mismetti, P | 1 |
| Auboyer, C | 1 |
| Samama, CM | 1 |
| Molliex, S | 1 |
| Levy, JH | 1 |
| Trudell, J | 1 |
| McMurdy, N | 1 |
| Penta de Peppo, A | 1 |
| Pierri, MD | 1 |
| Scafuri, A | 1 |
| De Paulis, R | 1 |
| Colantuono, G | 1 |
| Caprara, E | 1 |
| Tomai, F | 1 |
| Chiariello, L | 1 |
| Chen, RH | 1 |
| Frazier, OH | 1 |
| Cooley, DA | 1 |
| Menichetti, A | 1 |
| Tritapepe, L | 1 |
| Ruvolo, G | 1 |
| Speziale, G | 1 |
| Cogliati, A | 1 |
| Di Giovanni, C | 1 |
| Pacilli, M | 1 |
| Criniti, A | 1 |
| Haddy, SM | 1 |
| Shely, WW | 1 |
| Rice, N | 1 |
| Vander Salm, TJ | 1 |
| Kaur, S | 1 |
| Lancey, RA | 1 |
| Okike, ON | 1 |
| Pezzella, AT | 1 |
| Stahl, RF | 1 |
| Leone, L | 1 |
| Li, JM | 1 |
| Valeri, CR | 1 |
| Michelson, AD | 1 |
| Montesano, RM | 1 |
| Gustafson, PA | 1 |
| Palanzo, DA | 1 |
| Manley, NJ | 1 |
| Sadr, FS | 1 |
| Landymore, RW | 1 |
| Murphy, JT | 1 |
| Lummis, H | 1 |
| Carter, C | 1 |
| Lemmer, JH | 1 |
| Bennett-Guerrero, E | 1 |
| Sorohan, JG | 1 |
| Canada, AT | 1 |
| Ayuso, L | 1 |
| Newman, MF | 1 |
| Reves, JG | 1 |
| Mythen, MG | 1 |
| Pelletier, MP | 1 |
| Solymoss, S | 1 |
| Lee, A | 1 |
| Chiu, RC | 1 |
| Troianos, CA | 1 |
| Sypula, RW | 1 |
| Lucas, DM | 1 |
| D'Amico, F | 1 |
| Mathie, TB | 1 |
| Desai, M | 1 |
| Pasqual, RT | 1 |
| Pellegrini, RV | 1 |
| Newfeld, ML | 1 |
| Conley, JC | 1 |
| Plunkett, PF | 1 |
| Gans, H | 1 |
| Maineri, P | 1 |
| Covaia, G | 1 |
| Realini, M | 1 |
| Caccia, G | 1 |
| Ucussich, E | 1 |
| Luraschi, M | 1 |
| Crosta, A | 1 |
| Foresti, B | 1 |
| Chiaranda, M | 1 |
| Ray, MJ | 1 |
| Hales, MM | 1 |
| Brown, L | 1 |
| O'Brien, MF | 1 |
| Stafford, EG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss, Transfusion Index and Complications After Total Hip Replacement. A Prospective, Randomized, Double Blind Clinical Trial[NCT04187014] | Phase 2 | 90 participants (Actual) | Interventional | 2020-02-06 | Completed | ||
| Comparative Study of the Efficiency of Oral Tranexamic Tcid vs. Oral Tminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. A Prospective, Randomized, Double Blinded Controlled Clinical Trial.[NCT03365999] | Phase 2 | 92 participants (Actual) | Interventional | 2017-10-15 | Completed | ||
| Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.[NCT02579941] | 40 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding[NCT02492087] | Phase 3 | 84 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| The Effect of Intravenous E-Aminocaproic Acid (EACA) on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy (VRO)[NCT02257580] | Phase 4 | 28 participants (Actual) | Interventional | 2015-04-01 | Completed | ||
| The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery[NCT01728636] | Phase 2 | 61 participants (Actual) | Interventional | 2013-01-15 | Completed | ||
| Low Versus High Dose Tranexamic Acid in Adult Spinal Deformity Surgery: A Randomized, Blinded, Controlled Trial[NCT02053363] | Phase 2/Phase 3 | 64 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Aminocaproic Acid and Bleeding in Spinal Surgery[NCT00320619] | 182 participants (Actual) | Interventional | 2000-09-30 | Completed | |||
| Role of Topical Tranexamic Acid in Total Hip Arthroplasty[NCT01866943] | Phase 2 | 41 participants (Actual) | Interventional | 2011-11-30 | Terminated | ||
| Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial[NCT02829346] | Phase 2 | 60 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Evaluation of Tranexamic Acid Prior to Surgery in the Geriatric Hip Fracture Population for the Reduction of Post-Operative Blood Transfusion[NCT03923959] | Phase 3 | 400 participants (Anticipated) | Interventional | 2020-02-01 | Active, not recruiting | ||
| Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass (the OPTIMAL Study)[NCT03782350] | Phase 4 | 3,079 participants (Actual) | Interventional | 2018-12-26 | Completed | ||
| Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis Using an in Vitro Experimental Model of Fibrinolysis.[NCT02352675] | 40 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| Bradykinin Receptor Antagonism During Cardiopulmonary Bypass[NCT00223704] | Phase 2/Phase 3 | 150 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Topical Application of Tranexamic Acid to Reduce Postoperative Blood Loss in Posterior Approach Spinal Surgery[NCT02063035] | Phase 4 | 29 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851] | Phase 3 | 87 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| The Effect of Tranexamic Acid (TXA) on Blood Loss in Burn Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT03113253] | Phase 4 | 121 participants (Actual) | Interventional | 2016-09-22 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Incidence of VTE (symptomatic of DVT or PE), infection (superficial, deep), hematoma, seroma, reoperation, and death, measured in person-years ( x cases per 100,000 person years) (NCT02257580)
Timeframe: an expected average of 1 week (post-surgery), Follow-up at 6 weeks
| Intervention | cases per 100,000 person years (Number) |
|---|---|
| E-Aminocaproic Acid (EACA) | 0 |
| Placebo | 0 |
Determined by estimated blood volume, calculated using difference in preoperative and postoperative hemoglobin and applied to the Nadler equation for estimating blood volume while adjusting for transfused hemoglobin to produce a single metric of calculated intraoperative blood loss. (NCT02257580)
Timeframe: Intraoperative (3-6 hours)
| Intervention | mL (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 535.7 |
| Placebo | 628.0 |
Number of participants requiring 1 unit of intraoperative cell saver transfusion. Patients either received or did not receive intraoperative cell saver transfusion. The maximum number of intraoperative units transfused in this study was 1 unit. The count of participants in the data table refers to the number of patients who received this transfusion. (NCT02257580)
Timeframe: Intraoperative, 1 day
| Intervention | Participants (Count of Participants) |
|---|---|
| E-Aminocaproic Acid (EACA) | 7 |
| Placebo | 7 |
postoperative day of discharge after surgery- day of intake. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week
| Intervention | days (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 5.5 |
| Placebo | 5.1 |
24 hour drain output (mL) (NCT02257580)
Timeframe: Post-Surgery, 24 hours
| Intervention | mL (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 72.5 |
| Placebo | 103.3 |
The number of participants that required 1 unit of blood transfused post-operatively. Patients received blood if necessary post operatively, and the maximum number of units a patient received was 1. The count of participants refers to the number of patients who received this transfusion unit. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| E-Aminocaproic Acid (EACA) | 4 |
| Placebo | 3 |
Total additional blood products (fresh frozen plasma, cryoprecipitate, and platelets) transfused in the perioperative period measured in units. (NCT01728636)
Timeframe: 24 hours after skin incision
| Intervention | Units (Mean) |
|---|---|
| Tranexamic Acid | 1 |
| Placebo | 2 |
Estimated Intraoperative blood loss in milliliters (mLs) (NCT01728636)
Timeframe: Incision to skin closure (approximately 10 hours)
| Intervention | Milliliters (Mean) |
|---|---|
| Tranexamic Acid | 1550 |
| Placebo | 1600 |
Number of participants who experienced arterial or venous thromboembolism, neurologic complications (including stroke, seizure,and delirium), infections, and pulmonary renal or cardiac adverse outcomes (demand ischemia, myocardial infarction or new arrhythmia) before another operative procedure or hospital discharge. (NCT01728636)
Timeframe: Time of surgery to date of discharge from hospital (average 7 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 9 |
| Placebo | 9 |
Total operating room time from incision to closure of incision in minutes. (NCT01728636)
Timeframe: Minutes
| Intervention | Minutes (Median) |
|---|---|
| Tranexamic Acid | 602 |
| Placebo | 576 |
Total red blood cells transfused in the intraoperative period in (mL). Total RBC equal packed red blood cells and cell saver infusion. (NCT01728636)
Timeframe: Intraoperative period (approximately 12 hours)
| Intervention | milliliters (Median) |
|---|---|
| Tranexamic Acid | 1140 |
| Placebo | 1460 |
Total milligrams of intravenous tranexamic acid administered during the surgical procedure. (NCT01728636)
Timeframe: Intraoperative period
| Intervention | milligrams (Median) |
|---|---|
| Tranexamic Acid | 1408 |
| Placebo | 0 |
"To compare the estimated blood loss in patients undergoing complex, reconstructive, spinal fusion surgeries receiving one of two dosing protocols for the anti-fibrinolytic, TXA.~Estimated blood loss was calculated by suction canister volume minus intraoperative irrigation fluid plus blood content in sponges as estimated by weight for all cases." (NCT02053363)
Timeframe: This outcome is measured during surgery, from exposure to wound closure, approximately 8 hours.
| Intervention | mL (Mean) |
|---|---|
| High Dose/Study Group | 2046 |
| Standard of Care/Control | 1596 |
To compare the rates of intraoperative complications and 90 day complications observed in the two groups. (NCT02053363)
Timeframe: Perioperative complications were defined as complications occurring within 90 days of surgery.
| Intervention | Participants (Count of Participants) |
|---|---|
| High Dose/Study Group | 2 |
| Standard of Care/Control | 3 |
To compare the mean volume (mL) of packed red blood cell (PRBC) transfusions given to the two groups. Volumes of RBC vary from bag to bag and real volumes will be recorded as provided by the blood bank. (NCT02053363)
Timeframe: Participants will be followed for the duration of their hospital stay measured from day of surgery to day of discharge from the hospital, approximately 7 days.
| Intervention | mL (Mean) |
|---|---|
| High Dose/Study Group | 1259 |
| Standard of Care/Control | 935 |
Estimated Blood Loss defined as Pre Op Hgb mins the Post Op Day two Hgb. (NCT01866943)
Timeframe: Pre Op, Post Op Day 2
| Intervention | Hemoglobin (grams/deciliter) (Mean) |
|---|---|
| Baseline Population | 2.93 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 2 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 65.76 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 6 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 81.77 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: Preoperative
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 58.34 |
Measurement of the thigh at the half way point between the prominence of the greater trochanter and the lateral epicondyle of the femur. No data recorded at 2 weeks or 6 weeks for this study population. (NCT01866943)
Timeframe: Pre Op
| Intervention | centimeters (Mean) |
|---|---|
| Baseline Population | 52.99 |
Units of Packed Red Blood Cells Transfused (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days
| Intervention | units (Mean) |
|---|---|
| Placebo Group | 1.97 |
| Aminocaproic Acid Group | 1.41 |
| HOE 140 Group | 1.45 |
Units of plasma transfused (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days
| Intervention | units (Mean) |
|---|---|
| Placebo Group | 1.08 |
| Aminocaproic Acid Group | 0.68 |
| HOE 140 Group | 0.82 |
Blood product transfusion during hospitalization that included packed red blood cells, plasma, platelets and cryoprecipitate. (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Received any transfusion | Received packed red blood cells | Received plasma | Received platelets | Received cryoprecipitate | |
| Aminocaproic Acid Group | 56.8 | 48.6 | 24.3 | 16.2 | 2.7 |
| HOE 140 Group | 52.5 | 47.5 | 17.5 | 17.5 | 5.0 |
| Placebo Group | 47.4 | 36.8 | 31.6 | 23.7 | 10.5 |
D-dimer concentrations were measured at baseline, 30min and 60min of bypass, post-bypass and postoperative day 1 (NCT00223704)
Timeframe: Patients were followed from the start of surgery until postoperative day 1
| Intervention | ng/ml (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 30min of bypass | 60min of bypass | Post-bypass | Postoperative day 1 | |
| Aminocaproic Acid Group | 103.0 | 131.9 | 154.3 | 168.9 | 269.5 |
| HOE 140 Group | 88.1 | 209.0 | 363.3 | 858.5 | 337.3 |
| Placebo Group | 95.5 | 150.6 | 287.6 | 589.8 | 390.4 |
Interleukin-6 was measured at baseline, post-bypass and on postoperative day 1 and 2. (NCT00223704)
Timeframe: Patients were followed from the start of surgery until postoperative day 2
| Intervention | pg/ml (Mean) | |||
|---|---|---|---|---|
| Baseline | Post-bypass | Postoperative day 1 | Postoperative day 2 | |
| Aminocaproic Acid Group | 6.58 | 64.65 | 161.91 | 122.88 |
| HOE 140 Group | 4.80 | 142.02 | 166.27 | 86.54 |
| Placebo Group | 4.98 | 68.8 | 118.8 | 201.5 |
Blood loss following surgery was defined as the total amount of fluid collected from the drain in the wound site during the hospital stay. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 5 days
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 534 |
| Placebo | 530 |
Blood loss was calculated from the difference between the level of hemoglobin at the preoperative appointment and the lowest level during the postoperative hospitalization period. Reported here is the change in hemoglobin level after surgery. A negative number indicates a reduction in hemoglobin level. (NCT02063035)
Timeframe: From preoperative appointment approximately one week before surgery to end of hospital stay up to approximately 5 days after surgery
| Intervention | grams per deciliter (g/dL) (Median) |
|---|---|
| Tranexamic Acid | -3.2 |
| Placebo | -4.6 |
The number of days the participants stayed in the hospital after surgery was recorded. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 2 weeks
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 5 |
| Placebo | 6 |
All units of blood transfused during the hospital stay after surgery were recorded. One red blood cell unit contains 300 to 360 mL of whole blood. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 5 days
| Intervention | units of blood (Median) |
|---|---|
| Tranexamic Acid | 0 |
| Placebo | 0 |
Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 21 |
| Placebo | 13 |
To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative
| Intervention | mL (Mean) |
|---|---|
| Tranexamic | 727.6 |
| Placebo | 560.1 |
Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 1 |
| Placebo | 0 |
Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative
| Intervention | Units of packed red blood cells (Mean) |
|---|---|
| Tranexamic | 2.65 |
| Placebo | 2.36 |
16 reviews available for aminocaproic acid and Blood Loss, Postoperative
| Article | Year |
|---|---|
Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis.
Topics: Aminocaproic Acid; Anaphylaxis; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Su | 2022 |
Prophylactic Use of Antifibrinolytics During Pediatric Cardiac Surgery With Cardiopulmonary Bypass on Postoperative Bleeding and Transfusion: A Systematic Review and Meta-Analysis.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Component Transfusion; Cardiac Surgical | 2022 |
Efficacy and Safety of Antifibrinolytic Drugs in Pediatric Surgery: A Systematic Review.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Humans; Pharmaceutical Prep | 2021 |
Preventing perioperative bleeding in patients with inherited bleeding disorders.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Hemophilia A; Humans; Postoperativ | 2017 |
The Efficacy and Safety of Epsilon-Aminocaproic Acid for Blood Loss and Transfusions in Spinal Deformity Surgery: A Meta-Analysis.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Neurosu | 2019 |
Epsilon-aminocaproic acid versus tranexamic acid in total knee arthroplasty: a meta-analysis study.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; B | 2019 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Epsilon aminocaproic acid reduces blood transfusion and improves the coagulation test after pediatric open-heart surgery: a meta-analysis of 5 clinical trials.
Topics: Adolescent; Age Factors; Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation; Blood Coagul | 2015 |
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor IX; Factor VIII; Hemophilia | 2015 |
The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Coronary Artery | 2009 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Hum | 2011 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Erythrocyte Transfu | 2006 |
Pharmacologic methods to reduce perioperative bleeding.
Topics: Aminocaproic Acid; Aprotinin; Deamino Arginine Vasopressin; Hemorrhage; Hemostatics; Humans; Meta-An | 2008 |
Current antifibrinolytic therapy for coronary artery revascularization.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Coro | 2008 |
Antifibrinolytic therapy in cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Tests; Blood Loss, Surgical | 1995 |
22 trials available for aminocaproic acid and Blood Loss, Postoperative
| Article | Year |
|---|---|
Tranexamic acid or epsilon-aminocaproic acid in total joint arthroplasty? A randomized controlled trial.
Topics: Administration, Intravenous; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replace | 2019 |
First Comparative Study of the Effectiveness of the Use of Tranexamic Acid against ε-Aminocapróic Acid via the Oral Route for the Reduction of Postoperative Bleeding in TKA: A Clinical Trial.
Topics: Administration, Oral; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, K | 2021 |
Safety and efficacy of epsilon aminocaproic acid (EACA) as an antihemorrhagic drug in bilateral one stage total knee arthroplasty: A double-blind randomized controlled trial.
Topics: Administration, Intravenous; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replace | 2020 |
Tranexamic acid versus aminocapróic acid in multiple doses via the oral route for the reduction of postoperative bleeding in total primary hip arthroplasty: a prospective, randomized, double-blind, controlled study.
Topics: Administration, Oral; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, H | 2021 |
Blood Conservation Using Tranexamic Acid Is Not Superior to Epsilon-Aminocaproic Acid After Total Knee Arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2017 |
Intra-alveolar epsilon-aminocaproic acid for the control of post-extraction bleeding in anticoagulated patients: randomized clinical trial.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Anticoagulants; Antifibr | 2018 |
Intraoperative Use of Epsilon Amino Caproic Acid and Tranexamic Acid in Surgeries Performed Under Cardiopulmonary Bypass: a Comparative Study To Assess Their Impact On Reopening Due To Postoperative Bleeding.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Cardiopulmonary Bypass; Female; Humans; Male; Mid | 2015 |
Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Au | 2009 |
Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Au | 2009 |
Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Au | 2009 |
Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Au | 2009 |
Epsilon aminocaproic acid for the prevention of delayed postoperative bleeding in retired racing greyhounds undergoing gonadectomy.
Topics: Aminocaproic Acid; Animals; Dog Diseases; Dogs; Double-Blind Method; Female; Hemostatics; Hysterecto | 2012 |
Comparison of different doses of ε-aminocaproic acid in children for tetralogy of Fallot surgery: clinical efficacy and safety.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Cardiac Surgical Procedures; Child, Preschool; Dose-Resp | 2013 |
Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Transfusion; Bradykinin; Bradykinin Receptor Antag | 2013 |
Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation Tests; Blood Transfusion; | 2004 |
Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty--a prospective randomized double-blind placebo-controlled study.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Arthroplasty, Replac | 2005 |
Evaluation of Epsilon amino-caproic acid (EACA) and autologous blood as blood conservation strategies in patients undergoing cardiac surgery.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Autologo | 2006 |
Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Tests; Blood L | 1995 |
Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid.
Topics: Aminocaproic Acid; Aprotinin; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; Cardiopulm | 1996 |
Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Platelets; Cardiac Surgical Procedures; Double-Bli | 1996 |
The effect of low-dose epsilon-aminocaproic acid on patients following coronary artery bypass surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Coronary Artery Bypass; Female; Humans; Male; Postoperat | 1996 |
The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Aspirin; Coronary Artery Bypass; Dose-Respons | 1997 |
The effect of prophylactic epsilon-aminocaproic acid on bleeding, transfusions, platelet function, and fibrinolysis during coronary artery bypass grafting.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Platelets; Blood Transfusion; Coronar | 1999 |
Postoperative bleeding after coronary revascularization. Comparison between tranexamic acid and epsilon-aminocaproic acid.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Cardiopulmonary Bypass; Humans; Middle Aged; Postoperati | 2000 |
Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit.
Topics: Aged; Aminocaproic Acid; Aprotinin; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Disease | 2001 |
34 other studies available for aminocaproic acid and Blood Loss, Postoperative
| Article | Year |
|---|---|
Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; Posto | 2023 |
Epsilon Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Hip and Total Knee Arthroplasty.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
Topically Applied Epsilon-Aminocaproic Acid Reduces Blood Loss and Length of Hospital Stay After Total Knee Arthroplasty.
Topics: Administration, Topical; Aged; Aminocaproic Acid; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2017 |
Platelets and bleeding in the dental patient. It's not always from "blood thinners". Von Willebrand disease--clinical assessment and case report.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Platelets; Dental Care for Chronically Ill; Factor | 2013 |
Acquired von Willebrand syndrome with a type 2B phenotype: diagnostic and therapeutic dilemmas.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Autoantibodies; Blood Component Transfusion; Combined Mo | 2014 |
Association of Epsilon-Aminocaproic Acid With Blood Loss and Risk of Transfusion After Periacetabular Osteotomy: A Retrospective Cohort Study.
Topics: Acetabulum; Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blo | 2016 |
Comparative effectiveness of epsilon-aminocaproic acid and tranexamic acid on postoperative bleeding following cardiac surgery during a national medication shortage.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Cardiac Surgical Procedures; Cohort Studies; Comparative | 2016 |
Role of Amicar in surgery for neuromuscular scoliosis.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cas | 2008 |
How we treat: patients with haemophilia undergoing screening colonoscopy.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Colonoscopy; Factor IX; Hemophilia A; Hemophilia B; Huma | 2010 |
Control of life-threatening head and neck hemorrhage after dental extractions: a case report.
Topics: Aminocaproic Acid; Blood Transfusion; Deamino Arginine Vasopressin; Edema; Factor VII Deficiency; Fa | 2010 |
ε-Aminocaproic acid and clinical value in cardiac anesthesia.
Topics: Algorithms; Aminocaproic Acid; Anesthesia; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; | 2011 |
Tranexamic acid versus ɛ-aminocaproic acid: efficacy and safety in paediatric cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical Procedures; Cardiopu | 2011 |
High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Aortic Valve; Drug Administrati | 2011 |
Comparison of blood-sparing efficacy of ε-aminocaproic acid and tranexamic acid in newborns undergoing cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgica | 2011 |
Safety of tranexamic acid in pediatric cardiac surgery: what we do not know.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Cardiac Surgical Procedures; Female; Humans; Male; Posto | 2011 |
Haemostasis prophylaxis using single dose desmopressin acetate and extended use epsilon aminocaproic acid for adenotonsillectomy in patients with type 1 von Willebrand disease.
Topics: Adenoidectomy; Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Child; Child, Preschool; Deam | 2012 |
Switch from aprotinin to ε-aminocaproic acid: impact on blood loss, transfusion, and clinical outcome in neonates undergoing cardiac surgery.
Topics: Aminocaproic Acid; Aprotinin; Blood Transfusion; Cardiac Surgical Procedures; Female; Hemostatics; H | 2011 |
Can epsilon-aminocaproic acid balance the off-pump bleeding advantage?
Topics: Aged; Aminocaproic Acid; Assisted Circulation; Chi-Square Distribution; Coronary Artery Bypass; Coro | 2003 |
Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2003 |
[ON THE THERAPY OF POSTOPERATIVE HEMORRHAGE AND THROMBOSIS FOLLOWING PROSTATECTOMY WITH SPECIAL REFERENCE TO 6-AMINOCAPROIC ACID].
Topics: Aminocaproates; Aminocaproic Acid; Anticoagulants; Hematuria; Hemorrhage; Humans; Male; Postoperativ | 1963 |
[THERAPY OF POSTOPERATIVE HEMORRHAGE FOLLOWING PROSTATECTOMY WITH SPECIAL REFERENCE TO THE EFFECT OF 6-AMINOCAPROIC ACID].
Topics: Aminocaproates; Aminocaproic Acid; Fibrinolysis; Hemorrhage; Humans; Kallikreins; Male; Postoperativ | 1963 |
Identifying patients at risk of intraoperative and postoperative transfusion in isolated CABG: toward selective conservation strategies.
Topics: Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Anticoagulants; Blood Component Transfusion; Bloo | 2004 |
Morbidity and economic complications following mucogingival surgery in a hemophiliac HIV-infected patient: a case report.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Coagulants; Connective Tissue; Drug Costs; Factor | 2004 |
Case report: Glanzmann thrombasthenia. Dental patient management for a rare platelet disorder.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Platelets; Humans; Male; Platelet Aggregati | 2005 |
Disseminated intravascular coagulation unmasked by Mohs micrographic surgery.
Topics: Adenocarcinoma; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Carcinoma, Basal Cell | 2006 |
Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Factor VII; Factor VIIa; Hemorrhage; Humans; Infant, New | 2006 |
[The "Seville" Consensus Document on Alternatives to Allogenic Blood Transfusion. Sociedades españolas de Anestesiología (SEDAR), Medicina Intensiva (SEMICYUC), Hematología y Hemoterapia (AEHH), Transfusión sanguínea (SETS) Trombosis y Hemostasia (SETH)].
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Substitutes; Bloo | 2006 |
Fibrinogen levels following Amicar in surgery for idiopathic scoliosis.
Topics: Adolescent; Aminocaproic Acid; Child; Female; Fibrinogen; Humans; Male; Perioperative Care; Postoper | 2007 |
Intravascular thrombosis after exsanguination in a patient treated with epsilon-aminocaproic acid.
Topics: Aminocaproic Acid; Cardiopulmonary Bypass; Humans; Male; Middle Aged; Postoperative Hemorrhage; Thro | 1996 |
Use of epsilon-aminocaproic acid to reduce bleeding.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Hemostatics; Hum | 1997 |
epsilon-Aminocaproic acid plasma levels during cardiopulmonary bypass.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Body Weight; Cardiopulmonary Bypass; Chest Tubes; | 1997 |
Negative reexploration for cardiac postoperative bleeding: can it be therapeutic?
Topics: Aged; alpha-2-Antiplasmin; Aminocaproic Acid; Antifibrinolytic Agents; Antithrombins; Aortic Valve; | 1998 |
Antithrombin III in cardiac surgery: an outcome study.
Topics: Aminocaproic Acid; Anticoagulants; Antifibrinolytic Agents; Antithrombin III; Blood Transfusion; Car | 1998 |
Pharmacological control of bleeding during cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aortic Valve; Heart Valve Prosthesis Implantation; Human | 2000 |